EP1104460A1 - Modulation de l'apoptose a l'aide de bid - Google Patents

Modulation de l'apoptose a l'aide de bid

Info

Publication number
EP1104460A1
EP1104460A1 EP99937522A EP99937522A EP1104460A1 EP 1104460 A1 EP1104460 A1 EP 1104460A1 EP 99937522 A EP99937522 A EP 99937522A EP 99937522 A EP99937522 A EP 99937522A EP 1104460 A1 EP1104460 A1 EP 1104460A1
Authority
EP
European Patent Office
Prior art keywords
bid
polypeptide
cell
target cell
mutant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99937522A
Other languages
German (de)
English (en)
Inventor
Atan Gross
Stanley J. Korsmeyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Washington University in St Louis WUSTL
Original Assignee
University of Washington
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/136,879 external-priority patent/US6326354B1/en
Application filed by University of Washington, Washington University in St Louis WUSTL filed Critical University of Washington
Publication of EP1104460A1 publication Critical patent/EP1104460A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Definitions

  • BH3 only members include the mammalian proteins BID, BAD, BIK, RIM, BLK and HRK, as well as the EGL- 1 protein of C. elegans. Of note, all of these molecules are pro-apoptotic, lending credence to the thesis that BH3 represents a minimal death domain (Wang et al.,
  • apoptotic cells are eventually engulfed by neighboring cells or phagocytes, thereby avoiding an inflammatory response.
  • Necrosis is a pathological type of cell death observed following physical or chemical injury, exposure to toxins, or ischemia and characterized by swelling, rupture of the plasma membrane and cellular organelles, and in vivo inflammation due to release of the cellular content into the surrounding tissue. Hengartner, M., in Molecular Biolosv and Biotechnology. Robert A. Myers, ed., VCH Publishers, Inc., 1995, p. 158.
  • mutant pi 5 BID polypeptide and both types of mutant p22 BID polypeptides are intended to be included within the terms mutant BID or mutant BID polypeptide.
  • compositions comprising a pl5 BID polypeptide or a mutant BID polypeptide can be administered by any suitable route known in the art including, for example, intravenous, subcutaneous, intramuscular, transdermal, intrathecal or intracerebral or administration to cells in ex vivo treatment protocols. Administration can be either rapid as by injection or over a period of time as by slow infusion or administration of slow release formulation. For treating tissues in the central nervous system, administration can be by injection or infusion into the cerebrospinal fluid (CSF).
  • CSF cerebrospinal fluid
  • the pi 5 BID polypeptide or mutant BID polypeptide can also be administered with one or more agents capable of promoting penetration of the polypeptide across the blood- brain barrier.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention porte sur un nouveau polypeptide p15 BID ayant une activité agoniste de la mort cellulaire. Ce polypeptide p15 BID est produit par clivage de BID par médiation des caspases dans les cellules destinées à mourir, la mort étant induite par les récepteurs de TNT ou FAS. Le polypeptide p15 BID est utile dans des procédés de modulation de la mort d'une cellule cible qui consistent à traiter la cellule avec p15 BID. L'invention porte également sur des procédés d'inhibition de la mort cellulaire qui consistent à traiter une cellule cible avec un p15 BID mutant n'ayant pas d'activité agoniste de la mort cellulaire.
EP99937522A 1998-08-19 1999-07-28 Modulation de l'apoptose a l'aide de bid Withdrawn EP1104460A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/136,879 US6326354B1 (en) 1998-08-19 1998-08-19 Modulation of apoptosis with bid
US136879 1998-08-19
US13703898A 1998-08-20 1998-08-20
US137038 1998-08-20
PCT/US1999/016966 WO2000011162A1 (fr) 1998-08-19 1999-07-28 Modulation de l'apoptose a l'aide de bid

Publications (1)

Publication Number Publication Date
EP1104460A1 true EP1104460A1 (fr) 2001-06-06

Family

ID=26834712

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99937522A Withdrawn EP1104460A1 (fr) 1998-08-19 1999-07-28 Modulation de l'apoptose a l'aide de bid

Country Status (3)

Country Link
EP (1) EP1104460A1 (fr)
AU (1) AU5233799A (fr)
WO (1) WO2000011162A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503754B1 (en) 2000-09-07 2003-01-07 Isis Pharmaceuticals, Inc. Antisense modulation of BH3 interacting domain death agonist expression
WO2013192423A2 (fr) 2012-06-20 2013-12-27 Eutropics Pharmaceuticals, Inc. Méthodes et compositions utiles pour traiter les maladies impliquant des protéines de la famille bcl-2 avec des dérivés de quinoline
US20160038503A1 (en) 2012-11-21 2016-02-11 David Richard Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives
US10732182B2 (en) 2013-08-01 2020-08-04 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
EP3063302B1 (fr) 2013-10-30 2019-12-04 Eutropics Pharmaceuticals, Inc. Procédés de détermination de la chimiosensibilité et de la chimiotoxicité
KR20170126867A (ko) 2015-01-12 2017-11-20 유트로픽스 파마슈티컬스, 인크. 암 치료를 안내하기 위한 컨텍스트 의존성 진단 검사

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955593A (en) * 1996-09-09 1999-09-21 Washington University BH3 interacting domain death agonist

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0011162A1 *

Also Published As

Publication number Publication date
WO2000011162A1 (fr) 2000-03-02
AU5233799A (en) 2000-03-14

Similar Documents

Publication Publication Date Title
US6326354B1 (en) Modulation of apoptosis with bid
Torii et al. Human Daxx regulates Fas‐induced apoptosis from nuclear PML oncogenic domains (PODs)
Nagata Apoptotic DNA fragmentation
Gross et al. Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death
US5965703A (en) Human bad polypeptides, encoding nucleic acids and methods of use
US5998583A (en) BH3 interacting domain death agonist
EP0960124A1 (fr) Mutants a substitution serine de regulateur de mort de cellules associees a bcl-xl/bcl-2
US20050222029A1 (en) Compositions and methods for treating diseases
WO1999016787A9 (fr) Agonistes de mort cellulaire
US20100021482A1 (en) Novel death associated proteins, and thap1 and par4 pathways in apoptosis control
Holmgreen et al. Survival activity of Bcl-2 homologs Bcl-w and A1 only partially correlates with their ability to bind pro-apoptotic family members
US20090011501A1 (en) Novel death domain proteins
US20100317592A1 (en) Chemokine-binding protein and methods of use
AU762719B2 (en) Bax-mediated apoptosis modulating reagents and methods
US6570002B1 (en) Inhibitor of programmed cell death
WO2000011162A1 (fr) Modulation de l'apoptose a l'aide de bid
WO2002005835A2 (fr) Modulation de l'apoptose
WO2000023083A1 (fr) Polypeptides bax tronques et neuroprotecteurs
KR20010082753A (ko) 세포사멸 억제단백질
Conus Interactions between members of the Bcl-2 family, other protein partners and new survival factors
EP1607101A1 (fr) Inhibiteur de la degradation de la proteine interagissant avec la proteine x du virus de l'hepatite b
Huang Cloning and characterization of insect genes involved in programmed cell death
Krieser The study of an endonuclease and its potential role in apoptosis
McDonald III Determinants of killer/DR5 signaling and death ligand sensitivity

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010319

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20010906

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030903

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1036304

Country of ref document: HK